Aperio Group’s Juno Therapeutics, Inc. JUNO Stock Holding History

Aperio Group’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-29,949	Closed	-$1.37M	–	2298
2017 Q4	$1.37M	Buy	29,949 +395	+1%	+$19.7K	0.01%	1150
2017 Q3	$1.33M	Buy	29,554 +1,194	+4%	+$40.7K	0.01%	1126
2017 Q2	$848K	Buy	28,360 +3,024	+12%	+$74.6K	0.01%	1326
2017 Q1	$562K	Buy	25,336 +11,486	+83%	+$246K	﹤0.01%	1480
2016 Q4	$261K	Buy	+13,850	New	+$339K	﹤0.01%	1861

Other funds holding JUNO

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Aperio Group's JUNO Position: Q1 2018 in Review

Aperio Group sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 29,949 shares — an estimated $1.37M sold.

Aperio Group first reported a position in JUNO in Q4 2016 and held it in 5 quarters. The position peaked at $1.37M in Q4 2017. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

Aperio Group reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
Aperio Group sold 29,949 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $1.37M.
Aperio Group first reported a position in Juno Therapeutics, Inc. in Q4 2016 and held it in 5 quarters.
Aperio Group's Juno Therapeutics, Inc. position peaked at $1.37M in Q4 2017.
2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on Aperio Group's 13F filing for Q1 2018, filed 8 May 2018.